Literature DB >> 11045991

Mediators of the mitogenic action of human V(1) vascular vasopressin receptors.

M Thibonnier1, D M Conarty, C L Plesnicher.   

Abstract

Arginine vasopressin (AVP) activation of V(1) vascular receptors (V(1)Rs) stimulates cell growth and proliferation in different tissues via cellular signaling pathways that remain to be identified. To explore the intracellular mediators of the mitogenic action of V(1)R, Chinese hamster ovary (CHO) cells were stably transfected with the human V(1)R cDNA clone we isolated previously. We assessed AVP effects on kinase activation (immunoblotting with phosphospecific antibodies), DNA synthesis (tritiated thymidine uptake), cell cycle progression (flow cytometry analysis after nuclear labeling with propidium iodide), and cell proliferation (conversion of the colorimetric reagent MTS) in the presence or absence of various pathway inhibitors. AVP stimulation of V(1)Rs leads to the phosphorylation of several kinases, an increase in DNA synthesis, a progression through the S and G(2)-M phases of the cell cycle, and an increase in cell proliferation. The mediators of the mitogenic action of V(1)R activation included calcium mobilization, coupling to a G(q) protein, and the simultaneous and parallel activation of several kinases, mainly calcium/calmodulin-dependent kinase II, phosphatidylinositol 3 kinase, protein kinase C, and p42/p44 mitogen-activated protein kinase.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11045991     DOI: 10.1152/ajpheart.2000.279.5.H2529

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  6 in total

1.  Vasopressin protects hippocampal neurones in culture against nutrient deprivation or glutamate-induced apoptosis.

Authors:  J Chen; G Aguilera
Journal:  J Neuroendocrinol       Date:  2010-10       Impact factor: 3.627

2.  Arginine vasopressin receptor 1a is a therapeutic target for castration-resistant prostate cancer.

Authors:  Ning Zhao; Stephanie O Peacock; Chen Hao Lo; Laine M Heidman; Meghan A Rice; Cale D Fahrenholtz; Ann M Greene; Fiorella Magani; Valeria A Copello; Maria Julia Martinez; Yushan Zhang; Yehia Daaka; Conor C Lynch; Kerry L Burnstein
Journal:  Sci Transl Med       Date:  2019-06-26       Impact factor: 17.956

3.  An L-RNA-based aquaretic agent that inhibits vasopressin in vivo.

Authors:  Werner G Purschke; Dirk Eulberg; Klaus Buchner; Stefan Vonhoff; Sven Klussmann
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-17       Impact factor: 11.205

4.  Molecular mechanisms mediating the G protein-coupled receptor regulation of cell cycle progression.

Authors:  David C New; Yung H Wong
Journal:  J Mol Signal       Date:  2007-02-26

5.  Targeting the vasopressin type-2 receptor for renal cell carcinoma therapy.

Authors:  Sonali Sinha; Nidhi Dwivedi; Shixin Tao; Abeda Jamadar; Vijayakumar R Kakade; Maura O' Neil; Robert H Weiss; Jonathan Enders; James P Calvet; Sufi M Thomas; Reena Rao
Journal:  Oncogene       Date:  2019-10-15       Impact factor: 9.867

6.  dDAVP Downregulates the AQP3-Mediated Glycerol Transport via V1aR in Human Colon HCT8 Cells.

Authors:  Mariangela Centrone; Mariagrazia D'Agostino; Marianna Ranieri; Maria Grazia Mola; Pinuccia Faviana; Piero Vincenzo Lippolis; Domenico Alessandro Silvestris; Maria Venneri; Annarita Di Mise; Giovanna Valenti; Grazia Tamma
Journal:  Front Cell Dev Biol       Date:  2022-07-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.